Virological characteristics of the SARS-CoV-2 Omicron BA.2.75
Author:
Saito AkatsukiORCID, Tamura Tomokazu, Zahradnik Jiri, Deguchi Sayaka, Tabata Koshiro, Kimura Izumi, Ito Jumpei, Nasser Hesham, Toyoda Mako, Nagata Kayoko, Uriu Keiya, Kosugi Yusuke, Fujita Shigeru, Yamasoba Daichi, Shofa Maya, Begum MST Monira, Oda Yoshitaka, Suzuki Rigel, Ito Hayato, Nao Naganori, Wang Lei, Tsuda Masumi, Yoshimatsu Kumiko, Yamamoto Yuki, Nagamoto Tetsuharu, Asakura Hiroyuki, Nagashima Mami, Sadamasu Kenji, Yoshimura Kazuhisa, Ueno Takamasa, Schreiber Gideon, Takaori-Kondo Akifumi, Shirakawa Kotaro, Sawa Hirofumi, Irie Takashi, Takayama Kazuo, Matsuno Keita, Tanaka ShinyaORCID, Ikeda Terumasa, Fukuhara Takasuke, Sato Kei,
Abstract
AbstractSARS-CoV-2 Omicron BA.2.75 emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically different from BA.5, the currently predominant BA.2 descendant. Here, we showed that the effective reproduction number of BA.2.75 is greater than that of BA.5. While the sensitivity of BA.2.75 to vaccination- and BA.1/2 breakthrough infection-induced humoral immunity was comparable to that of BA.2, the immunogenicity of BA.2.75 was different from that of BA.2 and BA.5. Three clinically-available antiviral drugs were effective against BA.2.75. BA.2.75 spike exhibited a profound higher affinity to human ACE2 than BA.2 and BA.5 spikes. The fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were comparable to those of BA.5 but were greater than those of BA.2. Our multiscale investigations suggest that BA.2.75 acquired virological properties independently of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.
Publisher
Cold Spring Harbor Laboratory
Reference83 articles.
1. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5 2. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies 3. Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants 4. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies 5. Cao, Y. , Wang, J. , Jian, F. , Xiao, T. , Song, W. , Yisimayi, A. , Huang, W. , Li, Q. , Wang, P. , An, R. , et al. (2021). Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature, doi: https://doi.org/10.1038/d41586-41021-03796-41586.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|